PROSTIC

The centre of excellence is funded by a grant from the Prostate Cancer Foundation (PCF) and comprises a multi-disciplinary team including nuclear medicine, medical oncology, radiation oncology, urology and laboratory-based doctors and researches with a strong patient-centred philosophy.

ProsTIC performs state-of-the-art research to deliver new paradigms for treatment of prostate cancer driven by seamless integration of clinical trials, pre-clinical and discovery research. Follow us on Twitter for the latest updates.

ABOUT PROSTIC

ProsTIC at Peter Mac is a world-leader in theranostics.

THE PROSTIC TEAM

Meet the ProsTIC leadership team, scientific advisory team, CEO steering committee and staff.

WHAT IS PSMA THERANOSTICS?

This animation explains PSMA theranostics, a treatment that is increasingly being used for people with advanced prostate cancer and the focus of the world-leading research at ProsTIC at Peter Mac.

PROSTIC CLINICAL TRIALS

Clinical trials enable us to answer questions about what is the role of this new technology in improving patient care.

KEY RESEARCH

Radiolabelled prostate specific membrane antigen (PSMA) can be used for PET imaging and also treatment of patients with prostate cancer.

PROSTIC IN THE NEWS

ProsTIC’s world leading research in the news.

PARTNERS AND COLLABORATORS

Centres of Excellence do not evolve on their own. They require the best team, processes and purpose to realise a goal.